Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline
Deal gives Bayer gene therapy programs, manufacturing and technologies
The deal gives Bayer clinical and preclinical gene therapy programs, manufacturing capabilities and platform technologies.
Gene therapy company AskBio chose last year to raise VC cash and invest in its pipeline rather than continue to rely solely on licensing and transaction revenues that had kept it afloat since 2001. That decision primed the biotech for its takeout by Bayer on Monday